Inovio Pharmaceuticals Inc. [NASDAQ: INO] price plunged by -10.86 percent to reach at -$2.67. The company report on June 30, 2020 that INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19.
INO-4800 Selected for the U.S. Government’s Operation Warp Speed.
– 94% of Phase 1 trial participants demonstrated overall immune responses at Week 6 after two doses of INO-4800 in trial with 40 healthy volunteers in preliminary analyses.
A sum of 16792034 shares traded at recent session while its average daily volume was at 40.86M shares. Inovio Pharmaceuticals Inc. shares reached a high of $23.05 and dropped to a low of $21.52 until finishing in the latest session at $21.91.
The one-year INO stock forecast points to a potential upside of 1.88. The average equity rating for INO stock is currently 2.90, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Inovio Pharmaceuticals Inc. [INO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INO shares is $22.33 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INO stock is a recommendation set at 2.90. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
ROTH Capital have made an estimate for Inovio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Sell, with their previous recommendation back on July 01, 2020. The new note on the price target was released on July 01, 2020, representing the official price target for Inovio Pharmaceuticals Inc. stock. On June 26, 2020, analysts increased their price target for INO shares from 19 to 24.
The Average True Range (ATR) for Inovio Pharmaceuticals Inc. is set at 3.30, with the Price to Sales ratio for INO stock in the period of the last 12 months amounting to 1494.60. The Price to Book ratio for the last quarter was 14.80, with the Price to Cash per share for the same quarter was set at 1.52.
INO Stock Performance Analysis:
Inovio Pharmaceuticals Inc. [INO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.76. With this latest performance, INO shares dropped by -8.21% in over the last four-week period, additionally plugging by 416.75% over the last 6 months – not to mention a rise of 717.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INO stock in for the last two-week period is set at 47.91, with the RSI for the last a single of trading hit 41.93, and the three-weeks RSI is set at 51.24 for Inovio Pharmaceuticals Inc. [INO]. The present Moving Average for the last 50 days of trading for this stock 18.90, while it was recorded at 25.02 for the last single week of trading, and 8.59 for the last 200 days.
Insight into Inovio Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Inovio Pharmaceuticals Inc. [INO] shares currently have an operating margin of -2855.31. Inovio Pharmaceuticals Inc.’s Net Margin is presently recorded at -2902.75.
Return on Total Capital for INO is now -122.34, given the latest momentum, and Return on Invested Capital for the company is -127.11. Return on Equity for this stock declined to -264.15, with Return on Assets sitting at -84.31. When it comes to the capital structure of this company, Inovio Pharmaceuticals Inc. [INO] has a Total Debt to Total Equity ratio set at 2,896.79. Additionally, INO Total Debt to Total Capital is recorded at 96.66, with Total Debt to Total Assets ending up at 65.46. Long-Term Debt to Equity for the company is recorded at 2,836.39, with the Long-Term Debt to Total Capital now at 94.65.
Reflecting on the efficiency of the workforce at the company, Inovio Pharmaceuticals Inc. [INO] managed to generate an average of -$615,254 per employee. Receivables Turnover for the company is 1.35 with a Total Asset Turnover recorded at a value of 0.03.Inovio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.50 and a Current Ratio set at 8.50.
INO Stock EPS
With the latest financial reports released by the company, Inovio Pharmaceuticals Inc. posted -0.3/share EPS, while the average EPS was predicted by analysts to be reported at -0.27/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -11.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Inovio Pharmaceuticals Inc. go to 0.00%.
Inovio Pharmaceuticals Inc. [INO] Insider Position Details
There are presently around $964 million, or 27.20% of INO stock, in the hands of institutional investors. The top three institutional holders of INO stocks are: BLACKROCK INC. with ownership of 8,627,087, which is approximately 13% of the company’s market cap and around 1.60% of the total institutional ownership; VANGUARD GROUP INC, holding 5,594,111 shares of the stock with an approximate value of $122.57 million in INO stocks shares; and WASATCH ADVISORS INC, currently with $78.89 million in INO stock with ownership of nearly -51.879% of the company’s market capitalization.
Positions in Inovio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 127 institutional holders increased their position in Inovio Pharmaceuticals Inc. [NASDAQ:INO] by around 11,353,466 shares. Additionally, 53 investors decreased positions by around 15,333,802 shares, while 10 investors held positions by with 17,307,370 shares. The mentioned changes placed institutional holdings at 43,994,638 shares, according to the latest SEC report filing. INO stock had 76 new institutional investments in for a total of 5,603,453 shares, while 21 institutional investors sold positions of 1,794,306 shares during the same period.